Association between early bronchiolitis and the development of childhood asthma: a meta-analysis

ObjectiveEarly life bronchiolitis has been hypothesised to be associated with the subsequent risk of persistent wheezing or asthma. However, the link remains controversial. The objective of our study was to evaluate the association between bronchiolitis before 2 years of age and the late-onset wheezing/asthma.DesignSystematic review and meta-analysis.MethodsPubMed, Embase and Web of Science databases were systematically searched for studies published between 1955 and January 2020. Meanwhile, we also checked through the reference lists of relevant articles to see whether these references included reports of other studies that might be eligible for the review. Cohort and case–control studies assessing the association between early-life bronchiolitis and late-onset wheezing/asthma were included in this meta-analysis. Data were extracted by two independent reviewers. Results were pooled using a random-effects model or fixed-effects model according to the heterogeneity among studies.Results32 original articles with 292 844 participants, which met the criteria, were included in this meta-analysis. Bronchiolitis before 2 years of age was associated with an increased risk of subsequent wheezing/asthma (relative risk=2.46, 95% CI 2.14 to 2.82, p<0.001). After categorising studies into different groups based on age at the end of follow-up, geographical region and study quality, the association still remained significant.ConclusionsThe meta-analysis indicates an association between bronchiolitis before 2 years of age and the wheezing/asthma in later life. Well-designed and highly standardised prospective studies that better address bias due to potential confounding factors are needed to validate the risk identified in our meta-analysis.PROSPERO registration numberCRD42018089453.

Download Full-text

ASSOCIATION OF MMP-7 -181A>G POLYMORPHISM WITH COLORECTAL CANCER AND GASTRIC CANCER SUSCEPTIBILITY: A SYSTEMATIC REVIEW AND META-ANALYSIS

ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) ◽

10.1590/0102-672020190001e1449 ◽

2019 ◽

Vol 32 (3) ◽

Cited By ~ 1

Author(s):

Mohammad ZARE ◽

Jamal JAFARI-NEDOOSHAN ◽

Kazem AGHILI ◽

Hossein AHRAR ◽

Mohammad Hossein JARAHZADEH ◽

...

Keyword(s):

Colorectal Cancer ◽

Gastric Cancer ◽

Fixed Effects ◽

Cancer Susceptibility ◽

Meta Analysis ◽

Recessive Model ◽

Fixed Effects Model ◽

Case Control Studies ◽

Increased Risk ◽

The Matrix

ABSTRACT Introduction: The matrix metalloproteinase-7 (MMP-7) gene -181A>G polymorphism has been reported to be associated with colorectal cancer (CRC) and gastric cancer (GC) susceptibility, yet the results of these previous results have been inconsistent or controversial. Aim: To elaborate a meta-analysis to assess the association of -181A>G polymorphism of MMP-7 with CRC and GC risk. Methods: Published literature evaluating the association from PubMed, Web of Science, Google Scholar and other databases were retrieved up to April 25, 2018. Pooled odds ratio (OR) and 95% confidence interval (CI) were calculated using random- or fixed-effects model. Results: A total of 19 case-control studies, which included eleven studies on CRC (2,169 CRC cases and 2,346 controls) and eight studies on GC (1,545 GC cases and 2,366 controls) were identified. There was a significant association between MMP-7 -181A>G polymorphism and GC risk under the homozygote model (GG vs. AA: OR=1.672, 95% CI 1.161-2.409, p=0.006) and the recessive model (GG vs. GA+AA: OR=1.672, 95% CI 1.319-2.554, p=0.001), but not with CRC. By subgroup analysis based on ethnicity, an increased risk of CRC and GC was found only among Asians. Conclusions: This meta-analysis suggests that MMP-7 -181A>G polymorphisms is associated with GC risk, but not with CRC. However, our results clearly showed that the MMP-7 -181A>G polymorphism significantly increased the risk of CRC only in Asians.

Download Full-text

Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis

Virology Journal ◽

10.1186/s12985-021-01604-1 ◽

2021 ◽

Vol 18 (1) ◽

Author(s):

Yanli Liu ◽

Yilong Pan ◽

Yuyao Yin ◽

Wenhao Chen ◽

Xiaodong Li

Keyword(s):

Fixed Effects ◽

Meta Analysis ◽

Cochrane Library ◽

Case Control Studies ◽

Risk Of Death ◽

Potential Association ◽

Increased Risk ◽

Language Restriction ◽

Newcastle Ottawa Scale

Abstract Background The numbers of confirmed cases of coronavirus disease 2019 (COVID-19) and COVID-19 related deaths are still increasing, so it is very important to determine the risk factors of COVID-19. Dyslipidemia is a common complication in patients with COVID-19, but the association of dyslipidemia with the severity and mortality of COVID-19 is still unclear. The aim of this study is to analyze the potential association of dyslipidemia with the severity and mortality of COVID-19. Methods We searched the PubMed, Embase, MEDLINE, and Cochrane Library databases for all relevant studies up to August 24, 2020. All the articles published were retrieved without language restriction. All analysis was performed using Stata 13.1 software and Mantel–Haenszel formula with fixed effects models was used to compare the differences between studies. The Newcastle Ottawa scale was used to assess the quality of the included studies. Results Twenty-eight studies involving 12,995 COVID-19 patients were included in the meta-analysis, which was consisted of 26 cohort studies and 2 case–control studies. Dyslipidemia was associated with the severity of COVID-19 (odds ratio [OR] = 1.27, 95% confidence interval [CI] 1.11–1.44, P = 0.038, I2 = 39.8%). Further, patients with dyslipidemia had a 2.13-fold increased risk of death compared to patients without dyslipidemia (95% CI 1.84–2.47, P = 0.001, I2 = 66.4%). Conclusions The results proved that dyslipidemia is associated with increased severity and mortality of COVID-19. Therefore, we should monitor blood lipids and administer active treatments in COVID-19 patients with dyslipidemia to reduce the severity and mortality.

Download Full-text

The use of triclosan-coated sutures to prevent surgical site infections: a systematic review and meta-analysis of the literature

BMJ Open ◽

10.1136/bmjopen-2019-029727 ◽

2019 ◽

Vol 9 (9) ◽

pp. e029727 ◽

Cited By ~ 10

Author(s):

Imran Ahmed ◽

Adam Jonathan Boulton ◽

Sana Rizvi ◽

William Carlos ◽

Edward Dickenson ◽

...

Keyword(s):

Systematic Review ◽

Fixed Effects ◽

Primary Outcome ◽

Meta Analysis ◽

Surgical Site Infections ◽

Causative Factor ◽

Fixed Effects Model ◽

Surgical Interventions ◽

Registration Number ◽

Randomised Controlled

Introduction and objectivesSurgical site infections (SSIs) represent a common and serious complication of all surgical interventions. Microorganisms are able to colonise sutures that are implanted in the skin, which is a causative factor of SSIs. Triclosan-coated sutures are antibacterial sutures aimed at reducing SSIs. Our objective is to update the existing literature by systematically reviewing available evidence to assess the effectiveness of triclosan-coated sutures in the prevention of SSIs.MethodsA systematic review of EMBASE, MEDLINE, AMED (Allied and complementary medicine database) and CENTRAL was performed to identify full text randomised controlled trials (RCTs) on 31 May 2019.InterventionTriclosan-coated sutures versus non-triclosan-coated sutures.Primary outcomeOur primary outcome was the development of SSIs at 30 days postoperatively. A meta-analysis was performed using a fixed-effects model.ResultsTwenty-five RCTs were included involving 11 957 participants. Triclosan-coated sutures were used in 6008 participants and non triclosan-coated sutures were used in 5949. Triclosan-coated sutures significantly reduced the risk of SSIs at 30 days (relative risk 0.73, 95% CI 0.65 to 0.82). Further sensitivity analysis demonstrated that triclosan-coated sutures significantly reduced the risk of SSIs in both clean and contaminated surgery.ConclusionTriclosan-coated sutures have been shown to significantly reduced the risk of SSIs when compared with standard sutures. This is in agreement with previous work in this area. This study represented the largest review to date in this area. This moderate quality evidence recommends the use of triclosan-coated sutures in order to reduce the risk of SSIs particularly in clean and contaminated surgical procedures.PROSPERO registration numberCRD42014014856

Download Full-text

Lower circulating adiponectin is associated with higher risk of renal cell carcinoma: A meta-analysis

The International Journal of Biological Markers ◽

10.1177/1724600819898696 ◽

2020 ◽

Vol 35 (1) ◽

pp. 57-64

Author(s):

Jiajie Fang ◽

Xuanli Xu ◽

Qiqi Mao ◽

Yufan Ying ◽

Xu Zhang ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Fixed Effects ◽

Meta Analysis ◽

Significant Heterogeneity ◽

Healthy Controls ◽

Fixed Effects Model ◽

Increased Risk ◽

Carcinoma Risk

Background: Changes in circulating adiponectin have been related to the risks of various cancers. However, the association between circulating adiponectin and the risk of renal cell carcinoma has not been fully determined. A meta-analysis was performed to evaluate the relationship between circulating adiponectin and renal cell carcinoma risk. Methods: Observational studies that evaluated the association between circulating adiponectin and renal cell carcinoma risk were identified via a systematic search of PubMed and Embase databases. The difference between circulating adiponectin in renal cell carcinoma cases and healthy controls, and the multivariable adjusted association between circulating adiponectin and renal cell carcinoma risk were evaluated. A random effects model was used if significant heterogeneity existed; otherwise a fixed effects model was applied. Results: Eight case-control studies with 2624 renal cell carcinoma cases and 2904 healthy controls were included. Pooled results showed that circulating adiponectin was significantly lower in renal cell carcinoma cases than in healthy controls (mean difference = −1.08 ug/mL; 95% confidence interval (CI) −1.62, −0.54; P < 0.001). Higher circulating adiponectin was independently associated with a significantly lowered risk of renal cell carcinoma (adjusted odds ratio for 1 SD increment of adiponectin = 0.78; 95% CI: 0.63, 0.96; P = 0.02). Subgroup analyses according to characteristics including study design, ethnics of participants, blood samples, numbers of participants, mean ages of participants, and study quality showed consistent results. Conclusions: Lower circulating adiponectin is associated with increased risk of renal cell carcinoma. The potential pathophysiological mechanisms underlying the role of circulating adiponectin in the pathogenesis of renal cell carcinoma deserve further investigation.

Download Full-text

Quantitative assessment of the association between GRIA1 polymorphisms and migraine risk

Bioscience Reports ◽

10.1042/bsr20181347 ◽

2018 ◽

Vol 38 (6) ◽

Cited By ~ 2

Author(s):

Xueren Gao ◽

Jianguo Wang

Keyword(s):

Fixed Effects ◽

Meta Analysis ◽

Asian Population ◽

Pooled Analysis ◽

Case Control ◽

Large Sample Size ◽

Fixed Effects Model ◽

Case Control Studies ◽

Knowledge Infrastructure ◽

Online Databases

Purpose: The association between GRIA1 rs548294 G>A and rs2195450 C>T polymorphisms and migraine risk has been reported in several case–control studies. However, the results of studies are inconsistent. Thus, we conducted a meta-analysis to more precisely estimate the association of the two polymorphisms with migraine risk. Methods: Eligible studies were retrieved and screened from the online databases (EMBASE, PubMed, Web of Science, Wanfang, and Chinese National Knowledge Infrastructure). The pooled odds ratio (OR) with corresponding 95.0% confidence intervals (CIs) was assessed using random- or fixed-effects model. Results: A total of 1233 cases and 1374 controls from four eligible studies were included. The pooled analysis showed that GRIA1 rs548294 G>A polymorphism was not significantly associated with migraine risk. GRIA1 rs2195450 C>T polymorphism was significantly associated with migraine risk under heterozygous model (CT vs. CC, OR = 1.23, 95%CI = 1.02–1.48, PZ = 0.03). Further subgroup analysis based on ethnicity showed a significant association of GRIA1 rs2195450 C>T polymorphism with migraine risk in Asian population, but not in Caucasian population. Conclusions: Our results indicates that GRIA1 rs2195450 C>T polymorphism is significantly associated with migraine risk. However, the number of studies included in the meta-analysis was small. Thus, more high quality case–control studies with a large sample size are still required to confirm these findings.

Download Full-text

Cannabis Smoking And Risk Of Lung Cancer - A Systematic Review And Meta-Analysis

International Journal of Medicine and Surgery ◽

10.15342/ijms.v1i2.57 ◽

2014 ◽

Vol 1 (2) ◽

pp. 31-37 ◽

Cited By ~ 5

Author(s):

Khalid Bouti ◽

Rajae Borki ◽

Hicham Fenane ◽

Laila Harrak

Keyword(s):

Lung Cancer ◽

Systematic Review ◽

Fixed Effects ◽

Meta Analysis ◽

Case Control ◽

Cochrane Library ◽

Case Control Studies ◽

Open Access Journals ◽

Increased Risk ◽

Cannabis Smoking

Background: Cannabis is the illicit psychoactive substance the most consumed in the world. Little is known about the association between the use of cannabis and the risk of lung cancer. Objective:The objective of this meta-analysis is to determine whether use of cannabis is a risk factor for lung cancer. Methods: We conducted a systematic review and meta-analyses of all languages articles using relevant computerised databases. MEDLINE (online PubMed), Web of knowledge, Embase, EBSCO CINAHL, ScienceDirect, Scopus, Cochrane Library, and Directory of Open Access Journals were searched to September 2014 for cohorts and case-control studies that assessed the risk of lung cancer associated with cannabis smoking. The literature search was performed with a combination of medical subject headings terms, "cannabis" and "lung neoplasms". Data extraction: Two investigators independently analysed and extracted results from eligible studies. Our study's registration number on PROSPERO is CRD42014008872. Results: The search strategy identified 2476 citations. 13 studies were eligible for inclusion: 2 pooled analysis of 9 case-control studies, one case-control study and 3 cohorts. The cumulative analysis for all the studies under a fixed-effects model showed that cannabis smoking determined an increased risk of developing lung cancer in the future (relative risk 1.22, 95% confidence interval 0.999–1.5; p=0.051), with no evidence of heterogeneity across the studies (I2: 34%; p¼0.01). Conclusions: The use of cannabis with or without tobacco smoking is associated with an increased risk for lung cancer

Download Full-text

Methylation of Ecadherin gene is correlated with increased risk of nasopharyngeal carcinoma: A meta-analysis

ENGINEERING AND TECHNOLOGY ◽

10.46223/hcmcoujs.tech.en.9.1.349.2019 ◽

2020 ◽

Vol 9 (1) ◽

pp. 28-40

Author(s):

Truong Kim Phuong ◽

Lao Duc Thuan ◽

Nguyen Thi Hoang Trinh ◽

Nguyen Thi Phuong Dieu ◽

Nguyen Thi Le

Keyword(s):

Nasopharyngeal Carcinoma ◽

Promoter Methylation ◽

Fixed Effects ◽

Meta Analysis ◽

Nasopharyngeal Cancer ◽

Clinical Samples ◽

Fixed Effects Model ◽

Random Effects Models ◽

Increased Risk ◽

Data Heterogeneity

Background: The objective of this study was to estimate the correlation between the Ecadherin (CDH1) promoter methylation and the risk of nasopharyngeal cancer. Methods: Based on previous online articles for the evaluation the hypermethylated status of CDH1 gene at the promoter region with nasopharyngeal carcinoma, two independent reviewers selected studies through databases on PubMed, Google Scholar from 2001 to 2014. The software MedCalc® version 18.11 was applied for calculating pooled odd ratios (OR) with levels of data heterogeneity by the fixed and random effects models. Results: Of a total of 99 articles, 12 studies with 508 clinical samples of nasopharyngeal carcinoma patients and 282 normal samples were selected in the systematic review for meta-analysis. Overall, the results demonstrated the highly significant association between CDH1 promoter methylation with nasopharyngeal carcinoma under the fixed effects model (OR = 16.155, 95% CI: 8.533 - 30.585, p

Download Full-text

A Meta-Analysis for Association of ACE I/D Polymorphism with Susceptibility to Preterm Birth

World Journal of Peri & Neonatology ◽

10.18502/wjpn.v3i2.6157 ◽

2021 ◽

Author(s):

Reza Bahrami ◽

Seyed Alireza Dastgheib ◽

Hossein Golestanpour ◽

Elahe Akbarian ◽

Alireza Emarati ◽

...

Keyword(s):

Preterm Birth ◽

Fixed Effects ◽

Meta Analysis ◽

Recessive Model ◽

Biomedical Literature ◽

Case Control Studies ◽

China National Knowledge Infrastructure ◽

Pooled Data ◽

Increased Risk ◽

Study Heterogeneity

Background: Preterm birth is one of the main contributors to newborn mortality, morbidity, and hospitalization in the first year of life globally. To date, several numbers of studies have reported that Angiotensin-Converting enzyme Insertion/Deletion polymorphism (ACE I/D) is linked with preterm birth. But those results are conflicting. Thus, we carried out this meta-analysis to summarize the existing data and evaluated the association. Methods: All eligible studies were collected from PubMed, Scopus, SciELO, MedRxiv, SID, China National Knowledge Infrastructure (CNKI), and Chinese Biomedical Literature Database (CBLD) up to 01 March 2021. The pooled odds ratios (ORs) and 95% confidence interval (CIs) under all five genetic models were calculated using either random-effects or fixed-effects models dependent on study heterogeneity. Results: A total of five case-control studies with 480 preterm birth cases and 702 healthy subjects were included. Pooled data showed that the ACE I/D polymorphism was significantly associated with increased risk of preterm birth under the allele model (I vs. D: OR = 1.219, 95% CI 1.023-1.453, P = 0.027), homozygote model (II vs. DD: OR = 0.662, 95% CI 1.149-2.385, P = 0.007), and recessive model (DD vs. DI+II: OR = 0.707, 95% CI 1.082-1.948, P = 0.013). Stratified analysis by ethnicity indicated that the ACE I/D polymorphism was significantly associated with preterm birth in Caucasian descendants. Conclusion: Our pooled data revealed that ACE I/D polymorphism is associated with the risk of preterm birth. However, larger and more rigorous studies among different populations are needed to evaluate the association with preterm birth.

Download Full-text

Risk of skin rash with the proteasome inhibitor bortezomib: Updated systematic review and meta-analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.9092 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. 9092-9092

Author(s):

Emily Christine Case ◽

Shenhong Wu ◽

John F. Gerecitano ◽

Mario E. Lacouture

Keyword(s):

Skin Rash ◽

Proteasome Inhibitor ◽

Fixed Effects ◽

Meta Analysis ◽

Significant Risk ◽

Phase Iii ◽

High Grade ◽

Fixed Effects Model ◽

Increased Risk ◽

American Society

9092 Background: Rash is a common, adverse event to the novel proteasome inhibitor bortezomib (Velcade). Indicated for the treatment of multiple myeloma and mantle cell lymphoma, bortezomib is the first proteasome inhibitor approved by regulatory agencies. Because the incidence of bortezomib-induced skin rash varies widely in published manuscripts, we performed a systematic literature review and meta-analysis to determine the incidence and overall risk. Methods: We searched PubMed and Web of Science databases and abstracts presented at the American Society of Clinical Oncology and The American Society of Hematology annual meetings (1998 to July 2011) to identify relevant clinical studies. Eligible studies included prospective clinical phase II and phase III trials, with data on the incidence of rash in patients taking 1.3mg/m2, 1.5mg/m2, or 1.6 mg/m2 of bortezomib intravenously either weekly or twice weekly. The incidence of rash and relative risk (RR) were calculated using random-effects or fixed-effects model, depending on the heterogeneity of included studies. Results: A total of 2,616 patients with various hematologic and solid malignancies from 35 clinical trials were included for analysis. Among patients receiving twice weekly bortezomib, the summary incidence of all-grade and high-grade rash were 18.8 % (95% CI: 14.9% to 23.5%) and 3.6 % (95% CI: 2.3% to 5.7%), respectively. We found no significant increase in all grade rash incidence with higher doses of bortezomib: 19.3 % (95% CI: 15% to 24.5%) and 20.8% (95% CI: 11.6% to 34.4%) for doses of 1.3 mg/m2 and 1.5 mg/m2, respectively. In addition, bortezomib was associated with an increased risk in both all grade (RR: 19.70, 95% CI: 8.73 to 44.44, p<0.001) and high-grade rash (RR: 5.35, 95% CI: 2.16 to 13.29, p<0.001), compared to controls. Weekly bortezomib is associated with lower risk of rash compared to twice weekly dosing (incidence 3.9% versus 18.8%, p=0.001). Conclusions: Bortezomib is associated with a significant risk of developing rash with a higher risk among patients receiving twice weekly dosage. Management of rash to bortezomib is critical to prevent a negative effect on quality of life and dose modifications, both of which affect clinical outcome.

Download Full-text

Incidence and risk of neutropenia with palbociclib in patients with cancer: A systematic review and meta-analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.e12530 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. e12530-e12530

Author(s):

Yan Mao ◽

Janice Lu ◽

Haibo Wang ◽

Gang Nie

Keyword(s):

Systematic Review ◽

Fixed Effects ◽

Meta Analysis ◽

Significant Risk ◽

Metastatic Breast ◽

Progression Free Survival ◽

High Grade ◽

Fixed Effects Model ◽

Patients With Cancer ◽

Increased Risk

e12530 Background: Palbociclib is an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6 and has improved the progression-free survival of estrogen receptor positive, metastatic breast cancer (MBC). Its application in other cancers is also undergoing clinical evaluation. Neutropenia, especially high grade (grade 3 or 4), is one of the major side-effects of palbociclib, and the incidence was reported too vary in different studies. In order to better understand the overall risk of palbociclib associated neutropenia, we conducted a systematic review and meta-analysis. Methods: We conducted a systematic literature search (including Medline, Web of Science to November, 2016 and abstracts presented at the ASCO annual meetings from 2009 to 2016). Eligible studies include prospective clinical trials of patients with cancer treated with palbociclib on a 125mg daily 3/4 week schedule and have available data on neutropenia. The incidence and relative risk (RR) of neutropenia were calculated using a random-effects or fixed-effects model, depending on the heterogeneity of the included studies. Results: Eight studies published between 2012 and 2016 included a total of 1515 patients with cancer were eligible for analysis. For patients treated with palbociclib, the overall incidence of all-grade and high grade neutropenia were 77.4% (95% CI 70.9-82.8%) and 60.9% (57.8–63.8%), respectively. Surprisingly, the incidence of neutropenia was significantly different between MBC patients and non-MBC patients (all grade: RR 1.26 [95% CI 1.01–1.56], p = 0.041; high-grade: RR 1.57 [1.23–2.00], p = 0.000) who received palbociclib. Palbociclib was associated with a significantly increased risk of all-grade neutropenia in patients with cancer with an RR of 15.03 (10.17–22.21, p < 0.001) compared with controls. Conclusions: Patients with cancer who received palbociclib have a significant risk of developing neutropenia, especially MBC patients. It is strongly recommended to monitor these patients who are treated with palbociclib to adjust dose, treatment intervals, and avoid infections.

Download Full-text